236 related articles for article (PubMed ID: 20124460)
1. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.
Mitchell D; Pobre EG; Mulivor AW; Grinberg AV; Castonguay R; Monnell TE; Solban N; Ucran JA; Pearsall RS; Underwood KW; Seehra J; Kumar R
Mol Cancer Ther; 2010 Feb; 9(2):379-88. PubMed ID: 20124460
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the ALK1 ligands, BMP9 and BMP10.
Li W; Salmon RM; Jiang H; Morrell NW
Biochem Soc Trans; 2016 Aug; 44(4):1135-41. PubMed ID: 27528761
[TBL] [Abstract][Full Text] [Related]
3. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
[TBL] [Abstract][Full Text] [Related]
4. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.
Castonguay R; Werner ED; Matthews RG; Presman E; Mulivor AW; Solban N; Sako D; Pearsall RS; Underwood KW; Seehra J; Kumar R; Grinberg AV
J Biol Chem; 2011 Aug; 286(34):30034-46. PubMed ID: 21737454
[TBL] [Abstract][Full Text] [Related]
5. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
Cunha SI; Pardali E; Thorikay M; Anderberg C; Hawinkels L; Goumans MJ; Seehra J; Heldin CH; ten Dijke P; Pietras K
J Exp Med; 2010 Jan; 207(1):85-100. PubMed ID: 20065063
[TBL] [Abstract][Full Text] [Related]
6. BMP10 functions independently from BMP9 for the development of a proper arteriovenous network.
Choi H; Kim BG; Kim YH; Lee SJ; Lee YJ; Oh SP
Angiogenesis; 2023 Feb; 26(1):167-186. PubMed ID: 36348215
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms.
Salmon RM; Guo J; Wood JH; Tong Z; Beech JS; Lawera A; Yu M; Grainger DJ; Reckless J; Morrell NW; Li W
Nat Commun; 2020 Apr; 11(1):1621. PubMed ID: 32238803
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models of Hereditary Hemorrhagic Telangiectasia.
Hwan Kim Y; Vu PN; Choe SW; Jeon CJ; Arthur HM; Vary CPH; Lee YJ; Oh SP
Circ Res; 2020 Oct; 127(9):1122-1137. PubMed ID: 32762495
[TBL] [Abstract][Full Text] [Related]
9. Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors.
Al Tabosh T; Liu H; Koça D; Al Tarrass M; Tu L; Giraud S; Delagrange L; Beaudoin M; Rivière S; Grobost V; Rondeau-Lutz M; Dupuis O; Ricard N; Tillet E; Machillot P; Salomon A; Picart C; Battail C; Dupuis-Girod S; Guignabert C; Desroches-Castan A; Bailly S
Angiogenesis; 2024 May; 27(2):211-227. PubMed ID: 38294582
[TBL] [Abstract][Full Text] [Related]
10. ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.
Alsina-Sanchís E; García-Ibáñez Y; Figueiredo AM; Riera-Domingo C; Figueras A; Matias-Guiu X; Casanovas O; Botella LM; Pujana MA; Riera-Mestre A; Graupera M; Viñals F
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1216-1229. PubMed ID: 29449337
[TBL] [Abstract][Full Text] [Related]
11. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex.
Townson SA; Martinez-Hackert E; Greppi C; Lowden P; Sako D; Liu J; Ucran JA; Liharska K; Underwood KW; Seehra J; Kumar R; Grinberg AV
J Biol Chem; 2012 Aug; 287(33):27313-25. PubMed ID: 22718755
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
Upton PD; Davies RJ; Trembath RC; Morrell NW
J Biol Chem; 2009 Jun; 284(23):15794-804. PubMed ID: 19366699
[TBL] [Abstract][Full Text] [Related]
13. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
van Meeteren LA; Thorikay M; Bergqvist S; Pardali E; Stampino CG; Hu-Lowe D; Goumans MJ; ten Dijke P
J Biol Chem; 2012 May; 287(22):18551-61. PubMed ID: 22493445
[TBL] [Abstract][Full Text] [Related]
14. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.
David L; Mallet C; Mazerbourg S; Feige JJ; Bailly S
Blood; 2007 Mar; 109(5):1953-61. PubMed ID: 17068149
[TBL] [Abstract][Full Text] [Related]
15. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
Kim JH; Peacock MR; George SC; Hughes CC
Angiogenesis; 2012 Sep; 15(3):497-509. PubMed ID: 22622516
[TBL] [Abstract][Full Text] [Related]
16. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.
Mitrofan CG; Appleby SL; Nash GB; Mallat Z; Chilvers ER; Upton PD; Morrell NW
J Biol Chem; 2017 Aug; 292(33):13714-13726. PubMed ID: 28646109
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
David L; Mallet C; Keramidas M; Lamandé N; Gasc JM; Dupuis-Girod S; Plauchu H; Feige JJ; Bailly S
Circ Res; 2008 Apr; 102(8):914-22. PubMed ID: 18309101
[TBL] [Abstract][Full Text] [Related]
18. BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer.
Ouarné M; Bouvard C; Boneva G; Mallet C; Ribeiro J; Desroches-Castan A; Soleilhac E; Tillet E; Peyruchaud O; Bailly S
J Exp Clin Cancer Res; 2018 Aug; 37(1):209. PubMed ID: 30165893
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology.
Ruiz S; Chandakkar P; Zhao H; Papoin J; Chatterjee PK; Christen E; Metz CN; Blanc L; Campagne F; Marambaud P
Hum Mol Genet; 2017 Dec; 26(24):4786-4798. PubMed ID: 28973643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
